{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T20:54:36Z","timestamp":1760820876426,"version":"3.41.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.intimp.2017.03.006","type":"journal-article","created":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T21:18:00Z","timestamp":1488921480000},"page":"105-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Long-term effectiveness and safety of natalizumab in a Portuguese population"],"prefix":"10.1016","volume":"46","author":[{"given":"I","family":"Correia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Batista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Galego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"IB","family":"Marques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Jesus-Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AI","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MC","family":"Mac\u00e1rio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 6","key":"10.1016\/j.intimp.2017.03.006_bb0005","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00415-008-6011-0","article-title":"alpha4-Integrin antagonism with natalizumab: effects and adverse effects","volume":"255","author":"Stuve","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/j.intimp.2017.03.006_bb0010","unstructured":"Summary of product characteristics (Annex I) [http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000603\/WC500044686.pdf]."},{"issue":"9","key":"10.1016\/j.intimp.2017.03.006_bb0015","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.intimp.2017.03.006_bb0020","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2017.03.006_bb0025","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1212\/WNL.0000000000000541","article-title":"Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study","volume":"83","author":"O'Connor","year":"2014","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.intimp.2017.03.006_bb0030","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1136\/jnnp-2013-306936","article-title":"Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results","volume":"85","author":"Butzkueven","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.intimp.2017.03.006_bb0035","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1468-1331.2008.02517.x","article-title":"Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study","volume":"16","author":"Oturai","year":"2009","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.intimp.2017.03.006_bb0040","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1468-1331.2009.02728.x","article-title":"Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries","volume":"17","author":"Putzki","year":"2010","journal-title":"Eur. J. Neurol."},{"issue":"Suppl. 3","key":"10.1016\/j.intimp.2017.03.006_bb0045","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10072-010-0345-y","article-title":"Swedish natalizumab (Tysabri) multiple sclerosis surveillance study","volume":"31","author":"Piehl","year":"2011","journal-title":"Neurol. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2017.03.006_bb0050","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1177\/1352458510394701","article-title":"A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis","volume":"17","author":"Holmen","year":"2011","journal-title":"Mult. Scler."},{"issue":"Suppl. 3","key":"10.1016\/j.intimp.2017.03.006_bb0055","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10072-010-0344-z","article-title":"Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study","volume":"31","author":"Sangalli","year":"2011","journal-title":"Neurol. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2017.03.006_bb0060","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1017\/S0317167100011811","article-title":"The Toronto observational study of natalizumab in multiple sclerosis","volume":"38","author":"Krysko","year":"2011","journal-title":"Can. J. Neurol. Sci."},{"issue":"9","key":"10.1016\/j.intimp.2017.03.006_bb0065","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1007\/s00415-012-6414-9","article-title":"Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study","volume":"259","author":"Fernandez","year":"2012","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.intimp.2017.03.006_bb0070","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00415-011-6339-8","article-title":"Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis","volume":"259","author":"Melin","year":"2012","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.intimp.2017.03.006_bb0075","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/WNF.0b013e31824644e6","article-title":"Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort","volume":"35","author":"Kallweit","year":"2012","journal-title":"Clin. Neuropharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2017.03.006_bb0080","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s10072-012-1088-8","article-title":"Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice","volume":"34","author":"Lanzillo","year":"2013","journal-title":"Neurol. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2017.03.006_bb0085","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1159\/000351568","article-title":"Use of natalizumab in patients with active relapsing-remitting multiple sclerosis in Kuwait","volume":"22","author":"Alroughani","year":"2013","journal-title":"Med. Princ. Pract."},{"issue":"9","key":"10.1016\/j.intimp.2017.03.006_bb0090","doi-asserted-by":"crossref","first-page":"399","DOI":"10.33588\/rn.5909.2013479","article-title":"The efficacy and safety of natalizumab for the treatment of multiple sclerosis in Portugal: a retrospective study","volume":"59","author":"Sousa","year":"2014","journal-title":"Rev. Neurol."},{"issue":"6","key":"10.1016\/j.intimp.2017.03.006_bb0095","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40263-015-0251-1","article-title":"Platform therapy compared with natalizumab for multiple sclerosis: relapse rates and time to relapse among propensity score-matched US patients","volume":"29","author":"Johnson","year":"2015","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.intimp.2017.03.006_bb0100","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/ene.12992","article-title":"Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5years","volume":"23","author":"Zivadinov","year":"2016","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.intimp.2017.03.006_bb0105","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/039463201402700201","article-title":"Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy","volume":"27","author":"Totaro","year":"2014","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2017.03.006_bb0110","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s13760-014-0308-9","article-title":"Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program","volume":"114","author":"van Pesch","year":"2014","journal-title":"Acta Neurol. Belg."},{"issue":"2","key":"10.1016\/j.intimp.2017.03.006_bb0120","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.intimp.2017.03.006_bb0125","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1177\/1352458511399611","article-title":"Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis","volume":"17","author":"Phillips","year":"2011","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.intimp.2017.03.006_bb0130","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1007\/s00415-014-7325-8","article-title":"Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients","volume":"261","author":"Sorensen","year":"2014","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.intimp.2017.03.006_bb0135","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.msard.2014.09.186","article-title":"P037 - categorical change in T2 lesion volume and clinical outcomes in the Phase III FREEDOMS and its extension study, evaluating fingolimod in patients with relapsing-remitting multiple sclerosis","volume":"3","author":"Jeffery EVDC","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.intimp.2017.03.006_bb0140","first-page":"321","article-title":"An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis","volume":"52","author":"Horga","year":"2011","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.intimp.2017.03.006_bb0145","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.msard.2016.03.005","article-title":"Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"8","author":"Borchardt","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.intimp.2017.03.006_bb0150","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","article-title":"Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function","volume":"72","author":"Khatri","year":"2009","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.intimp.2017.03.006_bb0155","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1212\/WNL.0000000000001706","article-title":"Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS","volume":"85","author":"Kappos","year":"2015","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/j.intimp.2017.03.006_bb0160","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1212\/WNL.0000000000000283","article-title":"Fingolimod after natalizumab and the risk of short-term relapse","volume":"82","author":"Jokubaitis","year":"2014","journal-title":"Neurology"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576917300966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576917300966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T04:08:04Z","timestamp":1750046884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576917300966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":31,"alternative-id":["S1567576917300966"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2017.03.006","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term effectiveness and safety of natalizumab in a Portuguese population","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2017.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}